Here are the latest quarterly results of Aurobindo Pharma. For more details, see the Aurobindo Pharma financial fact sheet and Aurobindo Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Sep-18* |
3
Dec-18* |
3
Mar-19* |
3
Jun-19* |
3
Sep-19* |
3
Dec-19* |
3
Mar-20* |
3
Jun-20* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 47,514 | 52,697 | 52,922 | 54,446 | 56,005 | 57,994 | 61,584 | 59,248 | |
Other income | Rs m | 263 | 639 | 323 | 158 | 206 | 309 | 326 | 1,156 | |
Turnover | Rs m | 47,777 | 53,335 | 53,245 | 54,604 | 56,211 | 58,304 | 61,910 | 60,404 | |
Expenses | Rs m | 37,651 | 41,833 | 42,347 | 42,982 | 44,603 | 46,870 | 48,422 | 46,674 | |
Gross profit | Rs m | 9,594 | 10,613 | 10,215 | 11,337 | 11,275 | 11,951 | 13,285 | 12,574 | |
Depreciation | Rs m | 1,637 | 1,631 | 1,866 | 2,409 | 2,433 | 2,501 | 2,324 | 2,555 | |
Interest | Rs m | 354 | 477 | 501 | 499 | 409 | 371 | 318 | 211 | |
Profit before tax | Rs m | 7,866 | 9,144 | 8,170 | 8,587 | 8,638 | 9,388 | 10,968 | 10,964 | |
Tax | Rs m | 1,754 | 2,048 | 2,311 | 2,278 | 2,244 | 2,329 | 2,285 | 3,037 | |
Profit after tax | Rs m | 6,112 | 7,096 | 5,859 | 6,310 | 6,395 | 7,060 | 8,683 | 7,927 | |
Gross profit margin | % | 20.2 | 20.1 | 19.3 | 20.8 | 20.1 | 20.6 | 21.6 | 21.2 | |
Effective tax rate | % | 22.3 | 22.4 | 28.3 | 26.5 | 26.0 | 24.8 | 20.8 | 27.7 | |
Net profit margin | % | 12.9 | 13.5 | 11.1 | 11.6 | 11.4 | 12.2 | 14.1 | 13.4 | |
Diluted EPS | Rs | 10.4 | 12.1 | 10.0 | 10.8 | 10.9 | 12.1 | 14.8 | 13.5 | |
Diluted EPS (TTM) | Rs | 37.4 | 39.4 | 40.4 | 43.4 | 43.9 | 43.8 | 48.6 | 51.4 | |
![]() |
Read: Aurobindo Pharma 1QFY21 Result Performance Review
More Pharmaceuticals Company Quarterly Results: VENUS REMEDIES SUVEN LIFE SCIENCES NOVARTIS ALEMBIC SUN PHARMA
Compare AUROBINDO PHARMA With: VENUS REMEDIES SUVEN LIFE SCIENCES NOVARTIS ALEMBIC SUN PHARMA
Compare AUROBINDO PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
An Indian company founded three decades ago in a garage caught my attention...
In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More